Select Bibliography

Filter by any of these (after searching):

Sarkaria, J.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.

Jaeckle, K. A. , Anderson, S. K. , Kosel, M. , Sarkaria, J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N0272

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J Clin Oncol - 2011

Abstract - Primary - Preliminary - Neuro-Onc - NCCTG-N0572

FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K

Sarkaria, J. , Peller, P. , Galanis, E. , Jacobson, M. , Wu, W. ... - ASCO - J Clin Oncol - 2011

Abstract - Secondary - Primary - Neuro-Onc - NCCTG-N057K